Oruka Therapeutics (ORKA) Accounts Payables (2010 - 2026)

Oruka Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 3.3% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 3.3% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 20.02% from the prior year.
• Accounts Payables eased to $3.7 million in Q1 2026 per ORKA's latest filing, from $4.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.7 million in Q2 2025 and bottomed at $241000.0 in Q2 2023.
• The 5-year median for Accounts Payables is $1.0 million (2022), against an average of $1.7 million.
• Across the five-year window, Accounts Payables sank 78.29% in 2023 and soared 856.35% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $334000.0 in 2022, then grew by 8.38% to $362000.0 in 2023, then surged by 856.35% to $3.5 million in 2024, then grew by 20.02% to $4.2 million in 2025, then decreased by 11.87% to $3.7 million in 2026.
• Per Business Quant, the three latest ORKA Accounts Payables figures stand at $3.7 million (Q1 2026), $4.2 million (Q4 2025), and $2.2 million (Q3 2025).